Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifabutin Triple Therapy for H. pylori Infection
NCT04652284Phase 3Unknown
- Sponsor
- Rabin Medical Center
- Start
- May 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of rifabutin in Helicobacter pylori infection (3 arms), sponsored by Rabin Medical Center. Primary endpoint: Success of Helicobacter pylori treatment at 8 weeks. Status: unknown.
02
Drugs
rifabutin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT04652284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04652284.